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positive compared to only 11 % of healthy controls, 69 % 
RA or 71 % SLE patients had negative scores. The sensi-
tivity, specificity, positive predictive and negative predic-
tive value for having FM compared to controls was 93, 89, 
92 and 91 %, respectively (p < 2.2 × 10−16). Evaluating 
cytokine and chemokine profiles in stimulated cells reveals 
patterns that are uniquely present in patients with FM. This 
assay can be a useful tool in assisting clinicians in differen-
tiating systemic inflammatory autoimmune processes from 
FM and its related syndromes and healthy individuals.
Keywords Fibromyalgia · Rheumatoid arthritis · 
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Introduction
The differential diagnosis of rheumatic disorders involves 
distinguishing inflammation, degenerative changes and 
central sensitization from each other. Making this distinc-
tion is usually obvious or easily discernible on the basis of 
taking a history, performing a physical examination, view-
ing imaging studies as appropriate and obtaining laboratory 
analyses. There are occasions where traditional methods 
fail to either elicit a diagnosis or give the clinician clarity 
with regards to whether a patient, for example, is inflamed 
or has fibromyalgia (FM) [1].
Fibromyalgia has been a medical condition that for 
decades was relegated to being defined as a collection of 
subjective symptoms of varying characteristics lacking 
objective and reproducible laboratory features [2]. FM 
is estimated to afflict a population in the USA alone of 
between 2 and 5 % of the US population [3]. The annual 
cost of diagnosing FM makes it one of the most expensive 
Abstract Making a correct diagnosis is pivotal in the 
practice of clinical rheumatology. Occasionally, the con-
sultation fails to provide desired clarity in making labe-
ling an individual as having fibromyalgia (FM), systemic 
lupus erythematosus (SLE) or rheumatoid arthritis (RA). 
A chemokine and cytokine multiplex assay was devel-
oped and tested with the goal of improving and achieving 
an accurate differential diagnosis. 160 patients with FM, 
98 with RA and 100 with SLE fulfilling accepted criteria 
were recruited and compared to 119 controls. Supernatant 
cytokine concentrations for IL-6, IL-8, MIP-1 alpha and 
MIP-1 beta were determined using the Luminex multi-
plex immunoassay bead array technology after mitogenic 
stimulation of cultured peripheral blood mononuclear 
cells. Each patient’s profile was scored using a logisti-
cal regression model to achieve statistically determined 
weighting for each chemokine and cytokine. Among the 
477 patients evaluated, the mean scores for FM (1.7 ± 1.2; 
1.52–1.89), controls (−3.56 ± 5.7; −4.59 to −2.54), RA 
(−0.68 ± 2.26; −1.12 to −0.23) and SLE (−1.45 ± 3.34, 
−2.1 to −0.79). Ninety-three percent with FM scored 
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diagnostic processes linked to any illness [4] as it presently 
chiefly relies on using tests to “rule out” disorders of rheu-
matic, neurologic, psychiatric, hematologic and endocrine 
origins. Hence, finding an objective diagnostic methodol-
ogy offers substantial medical cost benefits. It additionally 
could lead to a potential way to monitor treatment efficacy 
as well as eliminate what has been an inexorable and pro-
longed pathway to an endpoint diagnosis that has previ-
ously utilized an indirect process of elimination.
In the last few years, laboratory panels have demon-
strated that the degree or intensity of inflammation, for 
instance, may be further elucidated by composite scores 
or weighted testing that are statistically significant (e.g., 
multibiomarker disease activity <Vectra> for RA, cell-
bound complement activation products <Avise> for SLE) 
[5, 6]. The multibiomarker disease activity index used in 
RA, for example, includes cytokine levels in its weighted 
scoring. In 2012, a group at the University of Illinois Col-
lege of Medicine evaluated 8 cytokines and chemokines 
in 110 FM patients and 91 matched healthy controls [7]. 
Unlike most previous studies, rather than measuring serum 
levels, peripheral blood mononuclear cells (PBMC) were 
stimulated by mitogens and in vitro production was quan-
titated. Statistically, significant findings distinguished 
the two groups as the FM group had 1.4-8 fold decreases 
in cytokine/chemokine production. Post hoc analy-
ses determined that the panel was just as accurate if four 
chemokines and cytokines (instead of eight) were studied. 
Since FM is common in patients with autoimmune disor-
ders, such as systemic lupus erythematosus (SLE) [8, 9], 
Sjogren’s Syndrome [10, 11] and rheumatoid arthritis 
(RA) [12], the chemokine/cytokine patterns found in FM 
patients may not have been unique to FM and were perhaps 
merely linked to rheumatic disorders as a whole, especially 
because of the frequent coexistence of FM and RA and FM 
and SLE. We therefore undertook comparative analyses to 
test the hypothesis that inflammation (represented by RA 
and SLE) and central sensitization syndromes (represented 
by FM) have distinct cytokine/chemokine signatures that 
could be clinically relevant.
Methods
A total of 160 FM patients diagnosed with FM for at least 
1 year were recruited to the study. Patients underwent two 
separate and independent physical examinations by two 
physicians to confirm that they met the American College 
of Rheumatology criteria [2]. All FM patients had discontin-
ued their FM-related medications for 2 weeks prior to test-
ing. One hundred SLE and 98 RA patients treated in Uni-
versity of Illinois College of Medicine were also studied. 
All fulfilled American College of Rheumatology criteria 
[13, 14]. Information regarding their demographics, disease 
duration and concurrent medication was collected (Table 1). 
Patients with SLE or RA who also had FM were excluded. 
The healthy controls were age- and sex-matched to the FM 
patients only and lacked a history of any type of chronic or 
acute illnesses and none were using any medications, over 
the counter or prescription drugs that had any known immu-
nologic effects. After obtaining IRB approved informed con-
sent, PBMC were obtained from each patient as described 
earlier [7]. Concentrations of live cells as well as percentages 
of dead cells in PBMC fractions were measured by using an 
automatic cell counter (Cellometer Auto 2000, Naxcelom 
Biosciences) according to the manufacturer’s instructions. 
These cells were cultured in the presence of the mitogenic 
activator phytohemagglutinin (PHA). After a culture time 
of 24 h, the resultant supernatant was harvested. Superna-
tant cytokine concentrations of interleukin-6, interleukin-8, 
macrophage inflammatory protein-1 alpha and macrophage 
inflammatory protein-beta (IL-6, IL-8, MIP-1a and MIP-1b) 
were determined using the Luminex multiplex immunoassay 
bead array technology [7]. Serial dilutions of cytokine stand-
ards were run in duplicates in each assay; their readings were 
used for calculating standard curves. In addition, pooled cul-
ture supernatants obtained from activated cell cultures served 
as a positive control. Fluorescence was measured using a 
MagPix fluorescence bead reader (Luminex).
Statistical analyses
Fluorescence intensities were transferred into R 
(http:www.r-project.org) statistical software [15] for con-
verting into concentration values. The standard curve was 
fitted with a 5-PL model, and the concentrations of the 
cytokines were quantified according to the curve. A two-
sided t test with unequal variance was used to test whether 
the mean concentrations of each cytokine were the same in 
the groups. The descriptive statistics of the groups as well 
as the p values of the t test were calculated by using the 
stats package for R.
We used function lrm* from package rms [16] in R 
software to determine a logistical regression model on the 
concentration of the cytokines described above as predictor 
Table 1  Characteristics of patients
Control FM RA SLE
Cohort size 119 160 98 100
Age
 Range 18–76 18–82 21–92 21–92
 Median 41 53.2 59 48
 Mean 40.8 52.2 58.1 49.6
Sex
 Female 101 98 86 94
 Male 18 12 12 6
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variables, and binary dependent variables and test scores 
were calculated.
The measured concentrations of the four cytokines, 
cIL-6, cIL-8, cMIP-1a and cMIP-1b, are combined into a sin-
gle score using the following formula: x = intercept + 
wIL-6cIL-6 + wIL-8cIL-8 + wMIP-1acMIP-1a + wMIP-1bcMIP-1b. 
Weights wIL-6, wIL-8, wMIP-1a and wMIP-1b, and intercept were 
determined experimentally by fitting a logistic regression 
curve. In addition, a cytokine/chemokine composite test 
score on the scale of 0–100 was calculated using the fol-
lowing formula:
Results
Fibromyalgia patients clearly had higher scores; the mean 
score was 1.7 ± 1.2, with 1.52–1.89 confidence interval 
which corresponds to 84.6 value of cytokine/chemokine 
test score on the scale of 0–100 (Table 2). The mean score 
of the control patients was −3.56 ± 5.7, with −4.59 to 
−2.54 confidence interval (cytokine/chemokine compos-
ite <CCC> test score 2.8). If a “profile” meant having a 
positive score (or greater than 50 on a scale of 100 for 
CCC test score), 93 % with FM and only 11 % of healthy 
controls met this benchmark. This was considered to 
be 93 % sensitive and 89.4 % specific for the diagno-
sis of FM when compared to the 119 controls (Table 3). 
The Wilcoxon test for FM versus healthy controls was 
p < 2.2 × 10−16, and the area under the receiver operat-
ing characteristic (ROC) curve was 0.96 (Fig. 1). Follow-
ing completion of this part of the protocol, 100 patients 
with SLE and 98 RA patients were studied. A total of 
71 % of those with SLE and 69 % with RA had negative 




scores (<50 on a scale of 100). The mean scores were 
−0.68 ± 2.26 for RA patients (−1.12 to −0.23 confi-
dence interval) and −1.45 ± 3.34 for SLE patients (−2.1 
to −0.79 confidence interval). Corresponding cytokine/
chemokine composite test scores were 33.7 and 19 on a 
scale of 100.
To better understand the statistical distribution of 
cytokine profile scores, each patient’s test score was 
calculated as a percentile rounded to the nearest integer 
on a scale of 1–100. There were two peaks in the scor-
ing distribution of the RA and SLE patients: one in the 
low score region (48 % with SLE and 42 % with RA 
for example had scores between 0 and 29) and a second 
smaller peak in the highest scoring region (25 % with 
SLE and 28 % with RA had scores between 70 and 100) 
(Fig. 2). This suggests that immune modulating agents, 
corticosteroids or concurrent FM in the autoimmune 
patients may account for the findings. Nevertheless, the 
SLE/RA versus FM scores achieved a significance of 
p < 2.2 × 10−16 as calculated by the Wilcoxon rank sum 
test. Concentrations of the studied cytokines in PBMC 
culture supernatants tended to be lower in FM patients 
compared to the autoimmune subjects, except for RA 
Table 2  Cytokine/chemokine composite (CCC) test scores of patients and healthy controls
Subjects tested Mean score 95 % Confidence interval CCC test score % Positive % Negative
Healthy controls 119 −3.56 ± 5.7 −4.59 to −2.54 2.8 13 (11 %) 106 (89 %)
FM 160 1.7 ± 1.2 1.52 to 1.89 84.6 149 (93 %) 11 (7 %)
RA 98 −0.68 ± 2.26 −1.12 to −0.23 33.7 30 (31 %) 68 (69 %)
SLE 100 1.45 ± 3.34 −2.1 to −0.79 19 29 (29 %) 71 (71 %)
Table 3  Characteristics of the CCC test scores in FM versus controls
Sensitivity 93 %
Specificity 89 %
Positive predictive value 92 %
Negative predictive value 91 %
Area under ROC curve 0.96
Wilcoxon test for FM scores versus controls p < 2.2 × 10−16























Fig. 1  Receiver operating characteristic (ROC) curve for CCC test 
scores of 160 FM patients and 119 controls. The area under the curve 
(AUC) is 0.96
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where IL-8 concentrations were similar (Table 4). Inter-
estingly, FM patients showed the lowest levels of IL-6 
compared to RA, SLE patients and controls—which were 
within 2 % of each other (p < 0.00001). Most of the auto-
immune patients disease was under good control with 
medication.
Discussion
Nearly 500 FM, autoimmune and healthy control patients 
underwent testing for cytokine/chemokine activity after 
mitogenic stimulation. Using a numerical score, all three 
groups had unique patterns with FM patients demonstrating 
less response to stimulation. This cytokine profile test had 
a 93 % sensitivity and an 89.4 % specificity for the diagno-
sis of FM. We also found that these profiles are relatively 
sensitive and specific for FM compared to SLE and RA. It 
remains unclear if these differences are directly related to 
the pathogenesis of FM.
We have been studying the role of cytokines in fibro-
myalgia for 30 years [17, 18]. Tumor necrosis factor and 
interleukins 1, 2, 6, 8 and 10 are associated with pain 
modulation, sleep induction, cognitive dysfunction, antin-
ociception and sympathetic nervous system homeostasis 
to varying degrees. Studies assessing serum levels in our 
opinion are unreliable due to short half-lives, circadian 
rhythms (time of day that the measurements are obtained) 
as well as target tissue variance. Published reports have 
not demonstrated a consistent FM pattern. A few studies 
have looked at cytokine function after mitogenic stimu-
lation. Patients with self-reported FM of <2 years dura-
tion had a greater response to stimulation than those with 
chronic FM [17]. This is consistent with findings from the 



















FM test score 
Fig. 2  The probability densities of CCC test scores of 119 controls, 
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National Institutes of Health that although serum cortisol 
levels are normal in the syndrome, response to cortrosyn 
stimulation is blunted [18]. Further work has suggested 
that sympathetic nervous system responses are less robust 
in FM when ascertained by decreased heart rate variability 
or exercise [19, 20].
The scores found in this report are consistent with the 
finding that chronic stress decreases cytokine/chemokine 
responses. IL-6 is an acute phase reactant that is associated 
with stress, fatigue, hyperalgesia and sympathetic nerv-
ous system activation; IL-8 induces chemotaxis, phagocy-
tosis, angiogenesis and modulates sympathetic mediated 
pain, and MIP-1 alpha and beta recruit polymorphonuclear 
cells and are chemoattractants for natural killer cells and 
monocytes. In all probability, chronic sensitization syn-
dromes (which includes FM) are associated with a milieu 
whereby responses to sympathetic, hormonal, cytokine and 
chemokine stimulation are diminished. In the last decade, it 
has also become evident that glial cells produce cytokines, 
and complex interactions in the setting of FM might 
explain opioid induced hyperalgesia observed in the syn-
drome [21]. In other words, FM patients often fare worse 
when prescribed narcotic analgesics.
The expression of serum cytokines and chemokines in 
RA and SLE is increased, and the use of anticytokine thera-
pies (and Phase 1 and 2 studies of chemokine inhibition) 
for autoimmune disease suggests that the findings would be 
opposite of what has been shown in FM [22].
Our study was confounded by different times of day that 
the cytokine/chemokine profile was obtained, concomitant 
anti-inflammatory and immune modulating medications, 
the use of corticosteroids and coexistence of FM in <10 % 
of the autoimmune (SLE and RA) patients. Despite this, we 
were able to demonstrate statistically significant differences 
in scores comparing patients with FM, healthy controls and 
autoimmune disease. The study was exploratory and pro-
vided preliminary information documenting a signal. Now 
that there is one, further data mining and/or a more focused 
second study would allow us to examine which subsets 
or autoimmune “phenotypes” are more likely to influence 
a combined chemokine score. This would, for example, 
include looking at established disease activity indices and 
acute phase reactants (e.g., sedimentation rate, C reactive 
protein). High cytokine/chemokine composite test scores 
strongly suggest a central sensitization component with or 
without an inflammatory condition. We posit that using a 
cytokine/chemokine stimulated response composite score is 
clinically useful in the differential diagnosis of FM patients 
as well as in patients where the role of inflammation versus 
central sensitization would benefit from further delineation. 
For example, changes in the score could be used to monitor 
response to different interventions.
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